 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Petros Pharmaceuticals partners with Idea Evolver

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in...

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals...

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company...

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway...

Petros Pharmaceuticals Provides Letter to Shareholders

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces...

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Petros Pharmaceuticals slips on $15M private placement financing

Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRANEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ('Petros' or 'the Company'), a pioneer in expanding consumer access to medication through the over...

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI Free Report)s stock price traded down 1.1% on Friday . The stock traded as low as $1.80 and last traded at $1.81. 8,840 shares changed hands during trading, a decline of 99% from the average session volume of 1,299,432 shares. The stock had previously closed...

Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 1.1%

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Market Cap	$2.88M
Volume (M)	79,952.00
52-Wk High	$9.54
52-Wk Low	$0.9172

Current Price	$1.44
Prev Close	$1.31
Open	$1.41
Dividend Yield	0.00%
50-Day Moving Average	$1.45
Beta	1.42
Avg. Volume	63,346.05
PE Ratio	-0.21

52-Week High	$9.54
52-Week Low	$0.9172
Market Capitalization	$2.88M
EPS	-$6.21
Price to Book	0.40
Revenue Per Employee	$291,030.88
Enterprise Value/EBITDA	0.87

PTPI Petros Pharmaceuticals Inc

About

Feed

News

Fundamentals